SERINA THERAPEUTICS INC. (SER) Fundamental Analysis & Valuation

NYSEARCA:SER • US81751A1088

Current stock price

1.98 USD
-0.02 (-1%)
At close:
1.9008 USD
-0.08 (-4%)
After Hours:

This SER fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SER Profitability Analysis

1.1 Basic Checks

  • SER had negative earnings in the past year.
  • In the past year SER has reported a negative cash flow from operations.
  • In the past 5 years SER always reported negative net income.
  • In the past 5 years SER always reported negative operating cash flow.
SER Yearly Net Income VS EBIT VS OCF VS FCFSER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • The Return On Assets of SER (-89.75%) is worse than 72.92% of its industry peers.
  • With a Return On Equity value of -633.01%, SER is not doing good in the industry: 79.30% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -89.75%
ROE -633.01%
ROIC N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SER Yearly ROA, ROE, ROICSER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

  • SER does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SER Yearly Profit, Operating, Gross MarginsSER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SER Health Analysis

2.1 Basic Checks

  • SER does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for SER. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SER Yearly Shares OutstandingSER Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SER Yearly Total Debt VS Total AssetsSER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • SER has an Altman-Z score of -9.68. This is a bad value and indicates that SER is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of SER (-9.68) is worse than 72.92% of its industry peers.
  • There is no outstanding debt for SER. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.68
ROIC/WACCN/A
WACC9.06%
SER Yearly LT Debt VS Equity VS FCFSER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 1.31 indicates that SER should not have too much problems paying its short term obligations.
  • SER has a Current ratio of 1.31. This is amonst the worse of the industry: SER underperforms 83.56% of its industry peers.
  • SER has a Quick Ratio of 1.31. This is a normal value and indicates that SER is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.31, SER is doing worse than 83.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 1.31
SER Yearly Current Assets VS Current LiabilitesSER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SER Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 7.27% on average over the next years.
  • Based on estimates for the next years, SER will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y27.71%
EPS Next 2Y20.9%
EPS Next 3Y15.44%
EPS Next 5Y7.27%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

SER Yearly Revenue VS EstimatesSER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2033 5M 10M 15M 20M 25M
SER Yearly EPS VS EstimatesSER Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. SER Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SER. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SER. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SER Price Earnings VS Forward Price EarningsSER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SER Per share dataSER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SER's earnings are expected to grow with 15.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.9%
EPS Next 3Y15.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SER Dividend Analysis

5.1 Amount

  • No dividends for SER!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SER Fundamentals: All Metrics, Ratios and Statistics

SERINA THERAPEUTICS INC.

NYSEARCA:SER (4/10/2026, 8:04:00 PM)

After market: 1.9008 -0.08 (-4%)

1.98

-0.02 (-1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25
Earnings (Next)05-11
Inst Owners3.51%
Inst Owner Change0%
Ins Owners6.3%
Ins Owner Change0%
Market Cap24.37M
Revenue(TTM)N/A
Net Income(TTM)-11.14M
Analysts80
Price Target13.26 (569.7%)
Short Float %1.97%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.52%
Min EPS beat(2)-53.76%
Max EPS beat(2)4.73%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 435.25
P/FCF N/A
P/OCF N/A
P/B 13.85
P/tB 13.85
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)-1.35
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -89.75%
ROE -633.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.95%
Cap/Sales 114.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.31
Quick Ratio 1.31
Altman-Z -9.68
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y27.71%
EPS Next 2Y20.9%
EPS Next 3Y15.44%
EPS Next 5Y7.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-71.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-134.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-133.54%
OCF growth 3YN/A
OCF growth 5YN/A

SERINA THERAPEUTICS INC. / SER Fundamental Analysis FAQ

What is the fundamental rating for SER stock?

ChartMill assigns a fundamental rating of 1 / 10 to SER.


What is the valuation status of SERINA THERAPEUTICS INC. (SER) stock?

ChartMill assigns a valuation rating of 0 / 10 to SERINA THERAPEUTICS INC. (SER). This can be considered as Overvalued.


What is the profitability of SER stock?

SERINA THERAPEUTICS INC. (SER) has a profitability rating of 0 / 10.


What is the expected EPS growth for SERINA THERAPEUTICS INC. (SER) stock?

The Earnings per Share (EPS) of SERINA THERAPEUTICS INC. (SER) is expected to grow by 27.71% in the next year.